Cite
Clinical safety, tolerability, pharmacokinetics and effects on urinary electrolyte excretion of AZD9977, a novel, selective mineralocorticoid receptor modulator.
MLA
Erlandsson, Fredrik, et al. “Clinical Safety, Tolerability, Pharmacokinetics and Effects on Urinary Electrolyte Excretion of AZD9977, a Novel, Selective Mineralocorticoid Receptor Modulator.” British Journal of Clinical Pharmacology, vol. 84, no. 7, July 2018, pp. 1486–93. EBSCOhost, https://doi.org/10.1111/bcp.13562.
APA
Erlandsson, F., Albayaty, M., Chialda, L., Ericsson, H., Amilon, C., Nelander, K., Jansson, L. R., Wernevik, L., Kjaer, M., Bamberg, K., & Hartleib, G. J. (2018). Clinical safety, tolerability, pharmacokinetics and effects on urinary electrolyte excretion of AZD9977, a novel, selective mineralocorticoid receptor modulator. British Journal of Clinical Pharmacology, 84(7), 1486–1493. https://doi.org/10.1111/bcp.13562
Chicago
Erlandsson, Fredrik, Muna Albayaty, Ligia Chialda, Hans Ericsson, Carl Amilon, Karin Nelander, Löfmark, Rasmus Jansson, et al. 2018. “Clinical Safety, Tolerability, Pharmacokinetics and Effects on Urinary Electrolyte Excretion of AZD9977, a Novel, Selective Mineralocorticoid Receptor Modulator.” British Journal of Clinical Pharmacology 84 (7): 1486–93. doi:10.1111/bcp.13562.